 | Adenosine Receptors in Neurology and Psychiatry This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on adenosine receptor science, providing insights useful for actual drug discovery/development in neurology and psychiatry areas. Akihisa Mori, PhD., Deputy Director, Strategic Product Portfolio Department, Kyowa Hakko Kirin Co., Ltd. Tokyo, Japan. He has been leading adenosine A2A receptor science, intensively and extensively researching and discovering physiological functions of adenosine A2A receptor for brain motor control, and through such a tremendous scientific work, has also been working for a first-in-class Adenosine A2A receptor antagonist as new medication for Parkinson's Disease, for more than 20 years, from its discovery stage to filing both US and Japan NDA, which has been launched in Japan (2013). He was graduated from Faculty of Pharmaceutical Sciences, Kyoto University in 1985, and obtained Ph.D. degree from Graduate School of Medicine and Faculty of Medicine, The University of Tokyo in 1996. With number of publications in peer review journals in neuroscience field (e.g., J. Neuroscience, Neurology, J. Physiology, Annals of Neurology, British J Pharmacology etc.), he has given more than 20 lectures/podium talks for academia/universities and international conferences on various subjects (e.g., neurophysiology, adenosine receptor science, Parkinson's Disease, global drug development etc.) held not only in Japan but also in UK, Germany, Australia, Austria, and USA. In summary, he has greatly been contributing to translate from basic science of adenosine biology to practical drug development for adenosine receptor ligand in neurology area. |
